Search Results

June 26, 2020

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus

June 15, 2020

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis

Phase 3 ANDROMEDA study investigated the first and only subcutaneous anti-CD38 monoclonal antibody in treatment of rare multi-system disease with a high unmet medical need andfor which there are currently no approved therapies Data selected as late-breaking abstract and featured in press briefing at European Hematology Association (EHA) Annual Congress

Global health equity

May 29, 2020

Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola Vaccine Regimen

The investigational Ebola vaccine regimen leverages Janssen’s established AdVac® and PER.C6® technologies and Bavarian Nordic’s MVA-BN® technology The AdVac® and PER.C6® technologies have been used to construct Janssen’s COVID-19, Zika, Respiratory Syncytial Virus (RSV) and HIV vaccine candidates

Global health equity

May 27, 2020

U.S. FDA Approves New Pediatric Formulation of SIRTURO® (bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis

Innovative Medicine

May 14, 2020

Janssen’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma

Longer-term follow-up data from Phase 1b/2 CARTITUDE-1 study demonstrate 100% overall response rate, 86% stringent complete response rate at a median of 11.5 months and 86% progression-free survival at 9 months

Global health equity

April 24, 2020

Statement of Support on Access to New COVID-19 Tools

Innovative Medicine

April 24, 2020

Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Submissions demonstrate Janssen’s commitment to developing new options for young patients

Global health equity

April 23, 2020

Global Advocacy and Communications Effort Launched to Drive Action Against COVID-19 and Stop Future Pandemics

South Africa’s Rugby World Cup Winning Captain Siya Kolisi kickstarts behavior change efforts “For Humankind”; calls on other stars from sports and screen to continue to rally around protective actions, like #MaskingForAFriend

Innovative Medicine

April 22, 2020

U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Patients ages 70 years or younger who were new to CLL treatment lived longer without disease progression with the IMBRUVICA®-based regimen compared to patients treated with a chemoimmunotherapy regimen

Innovative Medicine

April 3, 2020

Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST Journal

Panel of 19 Physicians Provided Consensus Opinions on Clinical Scenarios in Which They Considered Adding Oral PPAs in Patients with PAH on ERA + PDE-5 Inhibitor Background Therapy

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine